{
    "clinical_study": {
        "@rank": "45202", 
        "arm_group": [
            {
                "arm_group_label": "ALX-0171 Oral Inhalation - Single Dose (SD)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALX-0171 Oral Inhalation - Multiple Dose (MD)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "ALX-0171 Intravenous (IV)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The overall aims of the study are:\n\n        -  To provide additional information on the pharmacokinetics of ALX-0171 by measuring (i)\n           local (bronchoalveolar lavage fluid (BALF)) and systemic (plasma) concentrations of\n           ALX-0171 after oral inhalation, and (ii) systemic (plasma) and urine concentrations\n           after intravenous administration.\n\n        -  To further determine the safety and local and systemic tolerability of ALX-0171.\n\n        -  To further evaluate local (induced sputum) and/or systemic (serum) immunogenicity of\n           ALX-0171, by analysing the potential occurrence of anti-drug antibodies (ADA)."
        }, 
        "brief_title": "ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers", 
        "condition": [
            "Healthy", 
            "RSV Infection"
        ], 
        "condition_browse": {
            "mesh_term": "Respiratory Syncytial Virus Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Non-smoking healthy male volunteers, (18-55 years, extremes included).\n\n          2. Good health condition, as determined by medical history, physical examination and\n             clinical laboratory testing\n\n          3. Body mass index (BMI) within normal range: 18.0 \u2264 BMI < 30.0 (kg/m2)\n\n          4. Haematology and chemistry parameters within normal range, or showing no clinically\n             relevant deviations (as judged by the Investigator)\n\n          5. Heart rate and/or blood pressure within normal range (as judged by the Investigator)\n\n          6. Electrocardiogram (ECG) within normal range, or showing no clinically relevant\n             deviations (as judged by the Investigator)\n\n          7. Negative urine test for selected drugs of abuse at screening\n\n          8. Negative alcohol breath test upon check-in at study unit\n\n          9. Negative hepatitis panel (including hepatitis B surface antigen (HBsAg) and\n             anti-hepatitis C virus antibodies (anti-HCV)), and negative human immunodeficiency\n             virus (HIV) antibody screens\n\n         10. Willingness to consent to using an effective contraceptive method (by using 2 methods\n             of contraception in combination with a female partner: at least 1 of the\n             contraception methods must be a barrier contraception method, e.g., condom) during\n             the study and for at least 3 months after last study drug administration\n\n         11. Ability to comprehend and willingness to sign an Informed Consent Form (ICF)\n\n             For oral inhalation only:\n\n         12. Lung function test which shows a Forced Expiratory Volume in 1 second (FEV1) \u2265 90% of\n             predicted value\n\n         13. Ability to retro-breathe with nebulizer\n\n         14. Height between 170 and 190 cm (extremes included)\n\n         15. Ability to produce a sufficient amount of induced sputum (at least 400 \u03bcL containing\n             visual sputum plugs) to assess immunogenicity\n\n        Exclusion Criteria:\n\n          1. Current smokers, or ex-smokers abstinent from tobacco for less than one year, or a\n             history of smoking more than 10 packs a year\n\n          2. Symptomatic viral infection, or suspicion thereof (including rhinitis) in the last 14\n             days prior to dosing\n\n          3. Signs of active pulmonary infection or other pulmonary inflammatory conditions, even\n             in the absence of febrile episodes, in the last 14 days prior to dosing\n\n          4. History or presence of disease in the kidneys and/or heart, lungs, liver,\n             gastrointestinal tract, endocrine organs or other conditions such as metabolic\n             disease known to interfere with the absorption, distribution, metabolism or excretion\n             of drugs\n\n          5. Malignancy, or prior malignancy, with a disease-free interval of < 5 years after\n             diagnosis and intervention, except basal cell carcinoma (treated curatively)\n\n          6. Autoimmune disorders such as (but not limited to) lupus erythematosus, multiple\n             sclerosis, rheumatoid arthritis, or sarcoidosis.\n\n          7. History of hypersensitivity or allergies to any drug compound, including constituents\n             of ALX-0171\n\n          8. History of previous administration of ALX-0171, or any other inhaled biologic or drug\n             targeting the Respiratory Syncytial Virus (RSV) F protein. In any other case of use\n             of biologics: at least 6 months before administration of first study medication, or\n             the time of duration of the pharmacodynamic effect, or 10 times the half-life of the\n             respective drug, whatever is longer\n\n          9. Receipt of any investigational drug within 60 days prior to dosing\n\n         10. Intake of prescribed or over-the-counter medication within 14 days prior to dosing (\u2264\n             3 g/day paracetamol is allowed)\n\n         11. History or presence of alcohol or drug abuse\n\n         12. Blood donation (> 500 mL) or a comparable blood loss within three months prior to\n             dosing\n\n         13. Planned donation of germ cells, blood, organs, bone marrow during the course of the\n             study or within 6 months thereafter\n\n         14. Any other condition or prior therapy which, in the opinion of the Investigator, would\n             make the subject unsuitable for this study\n\n         15. Vulnerable subjects (e.g., persons kept in detention)\n\n             For oral inhalation only:\n\n         16. History or presence of atopy or any condition associated with airway\n             hyperresponsiveness (e.g., allergic or non-allergic asthma, chronic obstructive\n             pulmonary disease (COPD))\n\n         17. FEV1 drop of > 10% after inhalation of 4 mL of ALX-0171 placebo (measured at 5 min\n             after the end of inhalation)\n\n         18. Contra-indication for sputum induction, such as (but not limited to) recent eye\n             surgery, recent fractured ribs and recent (or history of) pneumothorax"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01875926", 
            "org_study_id": "ALX-0171-1.3/13", 
            "secondary_id": "2013-001425-71"
        }, 
        "intervention": [
            {
                "arm_group_label": "ALX-0171 Oral Inhalation - Single Dose (SD)", 
                "description": "single dose of 200 mg ALX-0171 via oral inhalation", 
                "intervention_name": "ALX-0171", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "ALX-0171 Oral Inhalation - Multiple Dose (MD)", 
                "description": "repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days", 
                "intervention_name": "ALX-0171", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "ALX-0171 Intravenous (IV)", 
                "description": "Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration", 
                "intervention_name": "ALX-0171", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium"
                }
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase I, Single-centre, Open-label Study to Evaluate the Pharmacokinetics of ALX-0171, Administered by Oral Inhalation or Intravenously, in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "Ablynx NV", 
            "last_name": "Steven De Bruyn, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicines and Health Products, FAMHP", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics: concentration of ALX-0171 after oral inhalation in BALF samples and in plasma samples", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 9"
            }, 
            {
                "measure": "Pharmacokinetics: ALX-0171 concentration in plasma and urine after intravenous administration", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 4"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01875926"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Lung function test pre- and post-inhalation with 4 mL of ALX-0171 placebo (on Day -1, applicable for oral inhalation only).\nLung function tests\nPhysical examination (including physical examination of the lung for oral inhalation)\nVital signs\n12-lead ECG.\nClinical laboratory\nLimited safety lab (haematology + limited chemistry).\nAdverse events (AEs) and concomitant medication", 
                "measure": "Safety and tolerability: safety markers", 
                "safety_issue": "Yes", 
                "time_frame": "from signing of Informed Consent Form (ICF) until last follow-up visit (i.e 35 to 42 days after first study drug administration)"
            }, 
            {
                "measure": "Immunogenicity: concentration of Anti-Drug Antibodies (ADA)in induced sputum (after oral inhalation only) and serum", 
                "safety_issue": "No", 
                "time_frame": "during screening until last follow-up visit (i.e. 35 to 42 days after first study drug administration)"
            }
        ], 
        "source": "Ablynx", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ablynx", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}